# Biotech Daily Digest — 2026-02-28

**14 items from 2 sources**

## Summary by Source

- Endpoints News: 9 items
- Fierce Biotech: 5 items


## Endpoints News

- **[GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more](https://endpoints.news/glp-1-news-galore-top-100-venture-investors-doug-ingram-to-step-down-and-more/)**  
  _Sat, 28 Feb 2026 11:00:37 +0000_  
  Happy Saturday, and welcome back to Endpoints Weekly. Our senior biopharma journalist Elizabeth Cairns covered a flurry of readouts this week from Eli Lilly and Novo Nordisk. We’ve summarized the data below, as well as ...

- **[Novartis, Takeda to enter next Medicare drug price negotiations](https://endpoints.news/novartis-takeda-to-enter-next-medicare-drug-price-negotiations/)**  
  _Fri, 27 Feb 2026 19:43:29 +0000_  
  At least two big pharma companies have said they will participate in the upcoming third round of Medicare negotiations under the Inflation Reduction Act, as court challenges against the program persist.

 Novartis confirmed to  ...

- **[Merck cuts more than 150 jobs at new Gardasil vaccine plant in North Carolina](https://endpoints.news/merck-cuts-more-than-150-jobs-at-new-gardasil-vaccine-plant-in-north-carolina/)**  
  _Fri, 27 Feb 2026 19:11:35 +0000_  
  Merck is shedding more than 150 jobs in North Carolina, almost all of which are tied to a vaccine manufacturing plant that was unveiled less than a year ago.

 The headcount reductions were disclosed in ...

- **[CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives](https://endpoints.news/chmp-recommends-modernas-flu-covid-shot-and-novartis-pill-for-hives/)**  
  _Fri, 27 Feb 2026 18:16:15 +0000_  
  The European Medicines Agency’s human medicines committee recommended approving six new medicines, including Moderna's flu-Covid-19 combo vaccine and Novartis' pill for hives.

 CHMP gives its recommendations to the European Commission, which has the final say ...

- **[Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design](https://endpoints.news/generatebiomedicines-raises-400m-ipo-ceo-talks-about-ais-future-in-drug-design/)**  
  _Fri, 27 Feb 2026 16:38:54 +0000_  
  A leader of the next wave of AI-driven biotechs completed one of the industry's largest IPOs in years, although the milestone was tarnished by a rough first few hours of trading for the new stock ...

- **[WuXi XDC makes an ADC linker deal with Earendil for up to $885M](https://endpoints.news/wuxi-xdc-makes-an-adc-linker-deal-with-earendil-for-up-to-885m/)**  
  _Fri, 27 Feb 2026 16:13:26 +0000_  
  WuXi Biologics' antibody-drug conjugate spinout WuXi XDC said on Friday that it will be working with Earendil Labs to develop new ADCs.

 AI-driven biologics developer Earendil will have access to WuXi ...

- **[Ginkgo divests biosecurity arm; J&J's early prostate cancer data](https://endpoints.news/ginkgo-divests-biosecurity-arm-jjs-early-prostate-cancer-data/)**  
  _Fri, 27 Feb 2026 15:14:31 +0000_  
  ⚠️ Ginkgo Bioworks' biosecurity deal: The company is selling its biosecurity unit to a "consortium of investors," which will operate it as a standalone business. In exchange, Ginkgo will get ...

- **[Padcev-Keytruda combo delivers more positive data in bladder cancer](https://endpoints.news/padcev-keytruda-combo-delivers-more-positive-data-in-bladder-cancer/)**  
  _Fri, 27 Feb 2026 15:00:05 +0000_  
  Researchers have rolled out another win for the Padcev-Keytruda combination, this time as a first treatment for a form of bladder cancer.

 It's the second recent win for the combo after last year's positive readout ...

- **[Novartis closes Avidity deal as rare heart disease spinout launches](https://endpoints.news/novartis-closes-avidity-deal-as-rare-heart-disease-spinout-launches/)**  
  _Fri, 27 Feb 2026 14:51:42 +0000_  
  Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies.

 The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/biontech-advances-dualitybio-adc-phase-3-half-patients-merck-daiichi-rival" hreflang="en">BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival</a>](https://www.fiercebiotech.com/biotech/biontech-advances-dualitybio-adc-phase-3-half-patients-merck-daiichi-rival)**  
  _Feb 27, 2026 9:34pm_  
  BioNTech and partner DualityBio are accelerating the development of their B7-H3 ADC into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). With encouraging phase 1/2 data, the partners are aiming to achieve success with a trial roughly half the size of the competing program from Merck & Co.…

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026" hreflang="en">Fierce Biotech Layoff Tracker 2026: Viatris cuts workforce by 10%; Merck makes cuts</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026)**  
  _Dec 23, 2025 10:11am_  
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle" hreflang="en">Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle</a>](https://www.fiercebiotech.com/biotech/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle)**  
  _Feb 27, 2026 1:05pm_  
  On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a $1 trillion valuation teaming up with a tech firm that has ridden the AI wave to a record-setting $5 trillion valuation of its own—a Wall Street supergroup, a la Cream, Audioslave or boygenius.

- **[<a href="https://www.fiercebiotech.com/biotech/atrium-arises-novartis-avidity-buy-270-million-and-pair-preclinical-cardio-candidates" hreflang="en">Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates</a>](https://www.fiercebiotech.com/biotech/atrium-arises-novartis-avidity-buy-270-million-and-pair-preclinical-cardio-candidates)**  
  _Feb 27, 2026 10:32am_  
  A new biotech has risen from the ashes of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement has now officially debuted as Atrium Therapeutics, with two preclinical cardio candidates in tow.

- **[<a href="https://www.fiercebiotech.com/biotech/generate-scores-largest-biotech-ipo-2024-400m-nasdaq-listing" hreflang="en">Behind Generate's 'feverish' race to raise $400M IPO while window remains open</a>](https://www.fiercebiotech.com/biotech/generate-scores-largest-biotech-ipo-2024-400m-nasdaq-listing)**  
  _Feb 27, 2026 3:38am_  
  Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers.
